Keywords: |
immunohistochemistry; signal transduction; cancer chemotherapy; protein expression; treatment outcome; treatment response; unclassified drug; overall survival; drug tolerability; review; cisplatin; fluorouracil; advanced cancer; diarrhea; drug efficacy; drug safety; side effect; treatment duration; clinical trials as topic; capecitabine; paclitaxel; disease free survival; metabolism; anemia; leukopenia; epidermal growth factor receptor 2; camptothecin; antineoplastic activity; carcinogenesis; gastrointestinal neoplasms; in situ hybridization; aspartate aminotransferase; immunotherapy; blood brain barrier; stomach cancer; targeted therapy; down regulation; receptor, erbb-2; loperamide; trastuzumab; oxaliplatin; esophagus cancer; alopecia; stomach neoplasms; lapatinib; stomach tumor; her2; pertuzumab; antibody dependent cellular cytotoxicity; clinical trial (topic); molecularly targeted therapy; erbb2 protein, human; cell dna; gastrointestinal tumor; antibody conjugate; immunoconjugates; molecular targeted therapy; immune modulation; chinese; procedures; esophagogastric cancer; trastuzumab emtansine; infusion related reaction; intention to treat analysis; humans; human; pembrolizumab; cell free dna; immunological antineoplastic agent; antineoplastic agents, immunological; antibody drug conjugate; trastuzumab deruxtecan; rc 48; tucatinib; zanidatamab; margetuximab; disitamab vedotin; retifanlimab; evorpacept
|